Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 230 participants.
Also called NCT01070030
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 230 participants
- Sponsor
- Registry
-
NCT01070030
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Thailand
- Registry status
- Completed
Technical summary
Registry record NCT01070030. Non-randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
- Acronym
- ACADEMY
- Condition
- Stage II Hypertension
- Intervention (Drug)
- Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01070030- Content hash
553f640122c757309f3d884877905b20dc28510b5f1a0e709fc0d155cf47a0a6